8 results about "Interleukin-1beta" patented technology

The invention discloses an application of hydrogen-rich water in improving chronic aluminum exposure mouse injury. The injury caused by chronic aluminum exposure comprises at least one of nerve injury, liver and kidney injury, intestinal barrier injury and blood brain barrier injury. The product is a beverage, a health care product or a medicine. The improvement effect is realized by adjusting a microorganism-intestinal-brain axis, including up-regulating the abundance of beneficial bacteria in the intestinal tract; the level of anti-inflammatory metabolites baicalein and indole-3-ethanol is increased, and the expression of inflammatory factors interleukin 6, interleukin 1 beta and tumor necrosis factor a is reduced; inflammation and oxidative stress reaction caused by chronic aluminum exposure can be remarkably relieved through hydrogen-rich water intervention, and meanwhile the liver and kidney functions can be effectively improved. In addition, abnormal behaviors of chronic aluminum exposure mice are improved, and the level of beta-amyloid protein in brains of the mice is remarkably reduced; the hydrogen-rich water is prompted to improve the abundance of beneficial bacteria, so that the bacteria have a protection effect on the organism with chronic aluminum exposure through the effects of resisting oxidation, resisting inflammation, protecting nerves and the like.

The invention belongs to the technical field of pharmacy, and discloses application of isoimperatorin in preparation of a medicine for treating fungal keratitis. The invention proposes that the isoimperatorin has a treatment effect on fungal keratitis for the first time. C57BL / 6 mice are adopted to establish a fungal keratitis model, the influence of isoimperatorin on model mouse cornea clinical score, neutrophil recruitment and interleukin 1 beta expression is researched, the influence of isoimperatorin on a TLR4 / MyD88 / IKK / NF-kappa B signal channel is verified, and meanwhile the influence of isoimperatorin on cell apoptosis and macrophage polarization is verified.

The application discloses a kind of split ring steroids and its preparation and application, by in vitro activity test evaluation, the compound of the present application can significantly inhibit interleukin 6 (IL-6) and interleukin 1 beta (IL-1 beta) release induced by lipopolysaccharide in macrophage RAW 264.7 in vitro, indicating that it has good anti-inflammatory activity.Therefore, it can be used for preparing new anti-inflammatory drugs.The present application provides a new source for the development of new anti-inflammatory drugs.

The invention provides application of CR-1-31-B in preparation of a medicine for preventing and / or treating inflammasome-related diseases, and belongs to the technical field of biological medicine manufacturing. The RNA helicase broad-spectrum inhibitor CR-1-31-B can be used for remarkably reducing the activation of cysteine proteinase-1 (Caspase-1) and the expression of interleukin 1 beta (IL-1beta) in mouse bone marrow-derived macrophages (BMDM), and reducing the occurrence of cell death events; meanwhile, in human mononuclear macrophage line THP1 cells, the CR-1-31-B is proved to be capable of obviously reducing the activation of Caspase-1 and the expression of IL-1beta, and the cell death is also obviously reduced. Therefore, the CR-1-31-B disclosed by the invention can be used for effectively inhibiting the activation of the inflammasome, so that a new means is provided for developing medicines for treating inflammasome-related diseases.

The present disclosure relates to methods of treating cancer comprising administering to a subject an IRAK4 modifying compound wherein the subject has irregular expression of a gene associated with NF-KB.

The present disclosure relates to methods of treating cancer comprising administering to a subject an IRAK4 modifying compound wherein the subject has irregular expression of a gene associated with NF-KB.

The invention belongs to the technical field of pharmacy, and discloses application of physcion in preparation of a medicine for treating fungal keratitis. The invention proposes that the physcion can inhibit the growth of corneal fungi for the first time, and has a treatment effect on fungal keratitis under in-vivo and in-vitro conditions. In an in-vivo experiment, a fungal keratitis model is established by adopting a C57BL / 6 mouse, and the influence of the physcion on the corneal clinical score of the model mouse, the recruitment of macrophages and neutrophils and the expression of NF-kB and interleukin 1beta is researched. In-vitro experiments prove that emodin monomethyl ether with different concentrations has an inhibiting effect on growth of aspergillus fumigatus, and meanwhile, an aspergillus fumigatus stimulated mouse macrophage model verifies the influence of emodin monomethyl ether on an NF-kB / IL-1beta signal channel.

The invention discloses application of dehydrocostus lactone and a medicine for treating steatohepatitis, relates to the technical field of biological medicines, and solves the problems that in the prior art, the application scene of the dehydrocostus lactone is limited, and the application of the dehydrocostus lactone in a complex pathological environment of metabolic dysfunction related steatohepatitis has a technical blank. Dehydrocostus lactone can reduce lipid accumulation, inflammation and fibrosis in liver cells; the weight, liver weight, serum triglyceride content, serum total cholesterol content and insulin resistance level of animals with steatohepatitis are reduced; the content of serum glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, tumor necrosis factor alpha, interleukin 1beta, malondialdehyde and bivalent ferrous ions is reduced, and the content of serum glutathione is increased; the compound can regulate and control lipid metabolism and mitochondrial energy metabolism pathways, reprograms fatty degeneration liver cell energy metabolism phenotypes, and is applied to preparation of drugs for treating steatohepatitis, ferroptosis inhibitors and glutamic oxalacetic transaminase and / or glutamic-pyruvic transaminase inhibitors.